

Oncology Today with Dr Neil Love: Front-Line Treatment of Chronic Lymphocytic Leukemia Edition (Interview Audio)

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- In patients with chronic lymphocytic leukemia (CLL), the presence of which of the following factors portends a poor prognosis?

  - Unmutated IGHV only
  - Mutated IGHV only
  - Either mutated or unmutated IGHV
- The iLLUMINATE trial evaluated which of the following BTK inhibitor-based therapies compared to standard chemoimmunotherapy in patients with treatment-naïve CLL?

  - Ibrutinib
  - Acalabrutinib
  - Zanubrutinib
- The Phase III ELEVATE-TN trial evaluating acalabrutinib as monotherapy or in combination with obinutuzumab compared to chlorambucil/obinutuzumab for patients with previously untreated CLL demonstrated which of the following outcomes?

  - No difference in progression-free survival (PFS) between the 3 treatment arms
  - Significant improvement in PFS in the acalabrutinib arms
- Which of the following disease-related factors puts a patient with CLL at high risk of developing tumor lysis syndrome from venetoclax therapy?

  - Lymphocyte count  $\geq 25 \times 10^9/L$  only
  - Lymph node  $\geq 5$  cm only
  - Lymphocyte count  $\geq 25 \times 10^9/L$  and lymph node  $\geq 5$  cm